WST (West Pharmaceutical Services) Moat Score: 8/10 (As of Jun. 27, 2026)


WST West Pharmaceutical Services Inc WST
95 GF Score
Price $350.85
GF Value $361.62
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is West Pharmaceutical Services Moat Score?

West Pharmaceutical Services WST +1.24% 95 Moat Score is 8 as of Jun. 27, 2026. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $361.62 (Fairly Valued). The stock has 9 warning signs investors should review. Among 846 Medical Devices & Instruments companies, West Pharmaceutical Services ranks better than 99.65% on this metric.

West Pharmaceutical Services has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

West Pharmaceutical Services has Wide Moat: West Pharmaceutical Services Inc has a robust wide moat due to its strong brand, significant intellectual property, and economies of scale in the healthcare sector. Its innovative R&D capabilities and strong pricing power further solidify its durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes West Pharmaceutical Services might have Wide Moat - Clear and robust wide moat.

West Pharmaceutical Services  (NYSE:WST) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

West Pharmaceutical Services Moat Score Related Terms

WST vs RMD, MDLN, SOLV: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Moat Score distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Moat Score falls into.


WST
95GF Score
West Pharmaceutical Services Inc WST
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
West Pharmaceutical Services (WST) has a Moat Score of 8 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, West Pharmaceutical Services ranks #3 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 0.40000000000001%.
Is West Pharmaceutical Services' Moat Score too high?
West Pharmaceutical Services' current Moat Score is 8. Based on the distribution chart, West Pharmaceutical Services ranks #3 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Moat Score compare to RMD and MDLN?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #3 out of 846 companies for Moat Score. This places West Pharmaceutical Services in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. West Pharmaceutical Services's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $361.62, compared to a current price of $350.85 — trading 3% below its estimated fair value. The current Moat Score is 8. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current Moat Score is 8 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (WST) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of $350.85 is trading 3% below its estimated GF Value™ of $361.62. GuruFocus considers West Pharmaceutical Services to be Fairly Valued.

Key valuation signals for WST:

  • Moat Score: 8
  • GF Value™: $361.62 vs. price of $350.85 (3% below fair value)
  • GF Score™: 95/100 with 9 warning signs

No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score

Get the complete analysis for WST

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$350.85
Price
$361.62
GF Value